Quantum mechanical/molecular mechanical and docking study of the novel analogues based on hybridization of common pharmacophores as potential anti-breast cancer agents

Parvin Asadi, Ghadamali Khodarahmi, Hossein Farrokhpour, Farshid Hassanzadeh, Lotfollah Saghaei

Abstract


In an attempt to identify some new potential leads as anti-breast cancer agents, novel hybrid compounds were designed by molecular hybridization approach. These derivatives were structurally derived from hybrid benzofuran–imidazole and quinazolinone derivatives, which had shown good cytotoxicity against the breast cancer cell line (MCF-7). Since aromatase enzyme (CYP19) is highly expressed in the MCF-7 cell line, the binding of these novel hybrid compounds to aromatase was investigated using the docking method. In this study, due to the positive charge on the imidazole ring of the designed ligands and also, the presence of heme iron in the active site of the enzyme, it was decided to optimize the ligand inside the protein to obtain more realistic atomic charges for it. Quantum mechanical / molecular mechanical (QM/MM) method was used to obtain more accurate atomic charges of ligand for docking calculations by considering the polarization effects of CYP19 on ligands. It was observed that the refitted charge improved the binding energy of the docked compounds. Also, the results showed that these novel hybrid compounds were adopted properly within the aromatase binding site, thereby suggesting that they could be potential inhibitors of aromatase. The main binding modes in these complexes were through hydrophobic and H bond interactions showing agreement with the basic physicochemical features of known anti aromatase compounds. Finally, the complex structures obtained from the docking study were used for single point QM/MM calculations to obtain more accurate electronic interaction energy, considering the electronic polarization of the ligand by its protein environment.


Keywords


QM/MM; Docking; Pharmacophore hybridization; Benzofuran-Imidazole; Quinazolinone

Full Text:

PDF

References


Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Euro J Cancer. 2010;46(4):765-781.

Osborne CK, Yochmowitz MG, Knight WA, Mcguire WL.The value of estrogen and progesterone receptors in the treatment of breast cancer.Cancer. 1980;46(12 Suppl):2884-2888.

Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res.1985;45(2):584-590.

Brodie A. Aromatase and its inhibitors--an overview. J Steroid BiochemMol Biol. 1991;40(1-3):255-261.

Lazar C, Kluczyk A, Kiyota T, Konishi Y. Drug evolution concept in drug design: 1. hybridization method. J Med Chem. 2004;47(27):6973-6982.

Abdel-Wahab BF, Awad GE, Badria FA. Synthesis, antimicrobial, antioxidant, antihemolytic and cytotoxic evaluation of new imidazole-based heterocycles.Eur J Med Chem. 2011;46(5):1505-1511.

Chen W, Deng XY, Li Y, Yang LJ, Wana WC, Wanga XQ, et al. Synthesis and cytotoxic activities of novel hybrid 2-phenyl-3-alkylbenzofuran and imidazole/triazole compounds. Bioorg Med ChemLett. 2013;23(15):4297-4302.

Wang D, Gao F. Quinazoline derivatives: synthesis and bioactivities. Chem Cent J.2013;7:95-110.

Roy PP, Roy K. Molecular docking and QSAR studies of aromatase inhibitor androstenedione derivatives. J Pharm Pharmacol. 2010;62(12):1717-1728.

Yurieva E, Agostinoa M, Ramsland PA. Challenges and advances in computational docking: 2009 in review. J MolRecognit. 2011;24(2):149-164.

Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking: current status and future challenges. Proteins. 2006;65(1):15-26.

Cho AE, Guallar V, Berne BJ, Friesner R. Importance of accurate charges in molecular docking:quantum mechanical/molecular mechanical (QM/MM) approach. J Comput Chem. 2005;26(9):915-931.

Al-ObaidAM, Abdel-Hamide SG, El-Kashef HA, Abdel-Aziz AA, El-Azab AS, Al-Khamees HA, et al. Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs. Eur J Med Chem. 2009,;44(6):2379-2391.

Khodarahmi GA, Smith HJ, Nicholls PJ, Ahmadi M. Enantioselectivity of some 1-(benzofuran-2-yl)-1-(1-H-imidazol-1-yl)alkanes as inhibitors of P450Arom. J Enz Inhibit. 2001;16:401-416.

Huey R, Morris GM. Using AutoDock with AutoDockTools: A Tutorial. The Scripps Research Institute Molecular Graphics Laboratory. California, USA. 2006.

Favia AD, Cavalli A, Masetti M, Carotti A, Recanatini M. Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins. 2006;62(4):1074-1087.

Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, et al. Gaussian development version, Revision B.01, Gaussian, Inc., Wallingford CT. 2009.

Dapprich S, Komaromi I, Byun KS, Morokuma K, Frisch MJ. A new ONIOM implementation in Gaussian98. Part I. The calculation of energies, gradients, vibrational frequencies and electric field derivatives. J MolStruct: THEOCHEM. 1999;462-462:1–21.

Suvannang N, Nantasenamat C, Isarankura-Na-Ayudhya C, Prachayasittikul V. Molecular docking of aromatase inhibitors. Molecules. 2011;16(5) :3597-3617.


Refbacks

  • There are currently no refbacks.